Effect of adding vildagliptin to start of insulin treatment in patients with type 2 diabetes.
Completed
- Conditions
- Diabetes
- Registration Number
- NL-OMON29400
- Lead Sponsor
- MCUtrecht
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1. Type 2 diabetes;
2. Failing on oral agents;
Exclusion Criteria
1. Pregnant women or women in the fertile period of life without adequate birth-control;
2. Type I DM, or secondary form of DM (eg pancreatic injury, prednisone induced);
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dose of insulin necessary for glycaemic control.
- Secondary Outcome Measures
Name Time Method Hypoglycemia <br>Weight <br>Blood pressure <br>Glycaemic variability <br>Glucagon dynamics<br>Lipids, markers of vascular function and inflammation and coagulation<br>Skin autofluorescence (AGE-level)